Geron Corporation (GERN)

NASDAQ: GERN · Real-Time Price · USD
1.265
+0.025 (2.02%)
Oct 15, 2025, 11:54 AM EDT - Market open
2.02%
Market Cap807.09M
Revenue (ttm)164.45M
Net Income (ttm)-88.01M
Shares Out 638.02M
EPS (ttm)-0.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,650,934
Open1.270
Previous Close1.240
Day's Range1.250 - 1.310
52-Week Range1.090 - 4.500
Beta0.57
AnalystsBuy
Price Target3.17 (+150.59%)
Earnings DateNov 6, 2025

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 1996
Employees 229
Stock Exchange NASDAQ
Ticker Symbol GERN
Full Company Profile

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $3.17, which is an increase of 150.59% from the latest price.

Price Target
$3.17
(150.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Geron Corporation Announces Executive Leadership Transitions and Appointments

Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commerc...

1 day ago - GlobeNewsWire

Making Money In Biotech Stocks

How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales ...

Other symbols: SNDX
5 days ago - Seeking Alpha

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an agg...

26 days ago - GlobeNewsWire

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on ...

6 weeks ago - Business Wire

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

2 months ago - GlobeNewsWire

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to...

2 months ago - Business Wire

Geron: I Think We've Seen This Movie Before

Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has alre...

2 months ago - Seeking Alpha

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Geron Corporation (NASDAQ:GERN) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim...

2 months ago - Seeking Alpha

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...

2 months ago - Business Wire

Geron Appoints Harout Semerjian as President and Chief Executive Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the ...

2 months ago - Business Wire

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and busi...

2 months ago - Business Wire

Conservative Vision Of A Positive Future For Geron

This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter s...

4 months ago - Seeking Alpha

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.

5 months ago - Business Wire

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

Geron's RYTELO faces limited revenue potential in a crowded MDS market, with predominantly 3L+ utilization and flat sequential growth. Despite a narrowed net loss, Geron remains unprofitable with no c...

5 months ago - Seeking Alpha

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm.

5 months ago - Business Wire

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Ron Maldiver - Investor Relations Dawn Bir - Interim President and Chief Executive Officer...

5 months ago - Seeking Alpha

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).

5 months ago - GlobeNewsWire

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...

5 months ago - Business Wire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Ne...

6 months ago - Accesswire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,00...

6 months ago - Business Wire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options

6 months ago - GlobeNewsWire

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

GERN's Rytelo showed promising sales growth, with Q4'24 net product revenue increasing by 68% to $47.5M from Q3'24's $28.2M. Despite initial optimism, the market is concerned about a potential plateau...

7 months ago - Seeking Alpha

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and busin...

7 months ago - Business Wire

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30...

Other symbols: CMRXCRVOCVSLLYNVOSEPN
7 months ago - Seeking Alpha

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

NEW YORK, NY / ACCESS Newswire / March 22, 2025 / Geron Corporation (NASDAQ:GERN) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties...

Other symbols: TBBK
7 months ago - Accesswire